Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells 6,500 Shares of Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 6,500 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total value of $937,625.00. Following the sale, the chief executive officer now directly owns 464,058 shares in the company, valued at $66,940,366.50. This represents a 1.38 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Jazz Pharmaceuticals Stock Up 0.9 %

Shares of NASDAQ:JAZZ opened at $140.23 on Thursday. The firm has a market cap of $8.52 billion, a P/E ratio of 19.75, a P/E/G ratio of 1.04 and a beta of 0.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The business has a fifty day simple moving average of $127.64 and a 200 day simple moving average of $119.71.

Institutional Trading of Jazz Pharmaceuticals

A number of large investors have recently bought and sold shares of JAZZ. Fuller & Thaler Asset Management Inc. grew its holdings in Jazz Pharmaceuticals by 117.4% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock worth $115,681,000 after acquiring an additional 507,234 shares during the period. Darwin Global Management Ltd. acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth about $59,668,000. Dimensional Fund Advisors LP grew its holdings in Jazz Pharmaceuticals by 18.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after acquiring an additional 320,724 shares during the period. Ameriprise Financial Inc. grew its holdings in Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock worth $225,076,000 after acquiring an additional 315,608 shares during the period. Finally, GMT Capital Corp grew its holdings in Jazz Pharmaceuticals by 140.0% during the 4th quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock worth $62,659,000 after acquiring an additional 296,800 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JAZZ has been the topic of a number of research analyst reports. Royal Bank of Canada reduced their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their target price for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $182.47.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.